| Filed On | Filing |
|---|---|
| 19 Mar 2026 |
8-K/A: Other Events
On March 18, 2026, the District Court for the District of New Jersey filed an order delaying the start of the bench trial between the Company and Hetero USA, Inc. from March 23, 2026 until May 18, 2026. The bench trial relates to the val... |
| 28 Aug 2025 |
8-K/A: Financial Statements and Exhibits
CORAL GABLES, Fla., August 26, 2025- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patie... |
| 10 Apr 2023 |
8-K/A: Financial Statements and Exhibits
On December 17, 2022, Catalyst Pharmaceuticals, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Eisai Co., Ltd. (“Eisai”). Pursuant to the terms of the Purchase Agreement, on January 24, 2023... |
| 07 Aug 2015 | 8-K/A: Entry into a Material Definitive Agreement |
| 25 Oct 2013 | 8-K/A: Submission of Matters to a Vote of Security Holders |
| 04 Jan 2013 | 8-K/A: Entry into a Material Definitive Agreement |
Loading...
